# EDGAR Filing Document

**Accession Number:** 0001962011
**File Stem:** 0001493152-26-025287
**Filing Date:** 2026-5
**Character Count:** 3367
**Document Hash:** 17c7cf06a692a17b591bc7830dbcee7f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-025287.hdr.sgml**: 20260526

**ACCESSION NUMBER**: 0001493152-26-025287

**CONFORMED SUBMISSION TYPE**: DEFA14A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260526

**DATE AS OF CHANGE**: 20260526

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Kairos Pharma, LTD.
- **CENTRAL INDEX KEY:** 0001962011
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 462993314
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEFA14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42275
- **FILM NUMBER:** 261021203

**BUSINESS ADDRESS:**
- **STREET 1:** 2355 WESTWOOD BLVD. #139
- **CITY:** LOS ANGELES
- **STATE:** CA
- **ZIP:** 90064
- **BUSINESS PHONE:** 818-404-5541

**MAIL ADDRESS:**
- **STREET 1:** 2355 WESTWOOD BLVD. #139
- **CITY:** LOS ANGELES
- **STATE:** CA
- **ZIP:** 90064

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 14A**

**Proxy Statement Pursuant to Section 14(a) of the**

**Securities Exchange Act of 1934**

Filed by the Registrant ☒ Filed by a party other than the Registrant ☐

Check the appropriate box:

☐ Preliminary Proxy Statement

☐ **Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**

☐ Definitive Proxy Statement

☒ Definitive Additional Materials

☐ Soliciting Material Under §240.14a-12

**Kairos Pharma Ltd.**

**(Name of Registrant as Specified In Its Charter)**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

**(Name of Person(s) Filing Proxy Statement, if other than the Registrant)** 

Payment of Filing Fee (Check the appropriate box):

☒ No fee required. <br> ☐ Fee paid previously with preliminary materials. <br> ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

**Supplement to** **PROXY STATEMENT FOR NOTICE OF 2026 ANNUAL MEETING OF <br> STOCKHOLDERS TO BE HELD JUNE 29, 2026**

 ****

***Explanatory Note***

On May 22, 2026, Kairos Pharma Ltd., a Delaware corporation (the "**Company**"), filed a definitive proxy statement (the "**Proxy Statement**") relating to the Company's 2026 Annual Meeting of Stockholders to be held on Monday, June 29, 2026, at 9:00 a.m. PDT / 12:00 p.m. EDT (the "**2026 Annual Meeting**"). You will be able to attend and participate in the 2026 Annual Meeting online by visiting www.virtualshareholdermeeting.com/KAPA2026.

The 2026 Annual Meeting is being held for the purposes set forth in the Proxy Statement, as supplemented and amended by this supplement (this "**Supplement**"). Capitalized terms not defined in this Supplement have the meanings set forth in the Proxy Statement.

This Supplement should be read in conjunction with the Proxy Statement.

 ****

***Supplement***

The Proxy Statement incorrectly stated that the record date for determining stockholders entitled to notice of and to vote at the 2026 Annual Meeting (the "**Record Date**") was May 15, 2026. The correct Record Date is May 18, 2026. Thus, only stockholders of record at the close of business on May 18, 2026 are entitled to notice of and to vote at the 2026 Annual Meeting and any adjournment or postponement thereof.

Except as set forth above, the Proxy Statement remains unchanged.